5 replies to this topic

[VP.]

Not ready for prime time.

We have intermediate results for the first 6 months of our epitalon mouse lifespan study, which we're presenting here. (Big thanks to our partners Ichor Therapeutics for making this possible.)

While the study is not complete, there does appear to be a difference between the treatment and control groups regarding lifespan thus far, as well as some of the other metrics of motor function.

Since this study is investigator-blinded, the two treatment arms are labeled Lifespan A and Lifespan B. However, the longer-lived lifespan arm (Lifespan B) is comparable to, not superior to, historical survival data for C57BL/6 mice, while the shorter-liived arm (Lifespan B) is shorter than historical survival data, which means that there's reason to be concerned that epitalon shortens, rather than lengthening, lifespan. Moreover, Lifespan B appears to be superior or equal to Lifespan A in all motor tests, so far, which is consistent with the hypothesis that the Lifespan A condition is non-beneficial.

However, this is still a highly preliminary guess.  More than 70% of the mice in both groups are still alive; the identity of each group is still blinded; and thus we'll have to wait for the completion of the study to get conclusive answers.

https://thelri.org/b...epitalon-study/

[pone11]

Can you update us on the mortality data for Lifespan A and B in this preliminary study?

[Tom Andre F. (ex shinobi)]

sorry but what about the control group ? its not clear or I miss something here

[male_1978]

sorry but what about the control group ? its not clear or I miss something here

 

The point is that the study is double-blind. We do not know whether the control group is Group A or Group B. 

 

Only thing we know is, that that one group performs similar and one performs worse than what was expected for normal mice.

 

So the wild speculation with preliminary data is that the group which performs "normal" is the placebo group and the group which performs "worse" is the threated group.

[ortcloud]

@VP.

 

Where can we find the dose amounts and schedule for the mouse study?

[VP.]

https://thelri.org/b...epitalon-study/

We now have 12-month data on our first mouse lifespan experiment, on the pineal-derived peptide Epitalon.  As always, we've uploaded the files to the experiment's OSF project.  Big thanks to our partners at Ichor Therapeutics!

As you can see, we've reached the 50% survival point, and there's no significant difference between the treatment and control groups (which are still labeled A and B; since this is a blinded experiment, we don't know which is which.)

Of course, there could still be an effect on maximal lifespan; we'll have to wait and see if the compound makes a difference there.

In terms of motor performance (a battery of tests for the mice's strength and endurance, which decline with age in mice as well as humans) we see no significant difference on the latest measurements in three out of four tests; the horizontal bar test (which measures coordination) continued to show significantly better mean performance for Group B than Group A.